With a recent survey announcing 49% of fertility patients questioned are suspending their treatments, three fertility experts tell HBI it’s becoming increasingly difficult to attract patients. Meanwhile, fertility group TFP looks no closer to sale.
Two of the US’s largest health insurers - Cigna and Humana - are reportedly in talks to merge. A stock-and-cash megadeal could be announced by the end of the year, but any deal will likely attract the interest of the regulator.
HT Medica, Spain's third largest private imaging provider by revenue, is being bought by pan-European PE firm Fremman Capital, reportedly for around €100m.
French nursing home operators have been under scrutiny since Orpea ran into well publicised difficulties two years ago, and the current economic climate has added to their woes. Facing persistent rumours it may be facing financial difficulties, elderly care group Medicharme tells HBI it is not on the brink of bankruptcy.
Last week French nursing home group Clariane (formerly Korian) announced the sale of assets totaling €1bn, with its Belgian assets tipped to be top of that list. Within days, the Belgian CEO of rival operator Orpea revealed that - contrary to some expert predictions - Orpea will remain in the region. What does this mean for the market?
HBI hears financial pressure on the UK NHS is making it increasingly difficult to outsource to the private sector – but with waiting lists worse than expected, there are still opportunities for for-profit operators. Who is most likely to take advantage?
Healthcare Business International has been bought by the premier relationship broker for the global private equity industry, IPEM, through its holding company Europevents Sas.
UAE-based healthcare provider PureHealth looks set to IPO in the coming months, with multiple sources suggesting it will list on the Abu Dhabi Securities Exchange.
Billionaire activist investor Paul Singer has acquired a minority stake in pan-European diagnostic labs group Synlab, just before the deadline for shareholders to decide whether they want to sell to PE firm Cinven, which is trying to take the group private. Singer appears to agree with Synlab's board that Cinven's €10-per-share offer doesn't reflect the true long-term value of the company.
The Dutch competition authority is looking to expand its influence over the healthcare sector, having already attempted to block some smaller M&A deals. HBI speaks to Rune Aresvik, founder of Dutch consultancy firm Vardetun, to understand what tighter regulations could mean for operators in the region.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.